ProMIS Neurosciences Inc

**Advances on Multiple Targets in AD & PD**

Based on our DCF model and a 15% discount rate, PMN is valued at approximately $7.00 per share. We apply a 7% probability of eventual sales of portfolio products in global markets.

Current Price (11/15/18) $0.26  
Valuation $7.00

---

**OUTLOOK**

ProMIS is developing a portfolio of monoclonal antibodies to address AD, ALS and PD. The company’s lead candidate, PMN310, is able to selectively target toxic oligomers which are thought to be the cause of neuron death in AD. Two proprietary, data-intensive algorithms are used to identify targets on misfolded proteins called ProMIS and Collective Coordinates which allow for precise and efficient target identification.

ProMIS anticipates launching its first in-human trial in 2019 following additional validation of lead candidate, PMN310. The indication has a target population of over 10 million patients in the US and over 40 million ex-US with dramatic expected increases over the next decades. There is no existing treatment therapy available, providing a strong case for pricing and penetration if the drug is approved.

With several other mAbs having navigated phased trials, there is a precedent for trial design, size and duration. Previous trial failures and additional research have narrowed down the optimal drug design and proper target. While still in early stage development, PMN310 makes a compelling case for success and should hold a dominant position in the market if trials are successful and regulatory approval is granted.

---

**SUMMARY DATA**

<table>
<thead>
<tr>
<th>Risk Level: Above Average</th>
<th>Type of Stock: Small-Growth</th>
<th>Industry: Med-Biomed/Gene</th>
</tr>
</thead>
</table>

**Revenue (in millions of $CAD)**

<table>
<thead>
<tr>
<th>Year</th>
<th>Q1 (Mar)</th>
<th>Q2 (Jun)</th>
<th>Q3 (Sep)</th>
<th>Q4 (Dec)</th>
<th>Year (Dec)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>$0.0 A</td>
<td>$0.0 A</td>
<td>$0.0 A</td>
<td>$0.0 A</td>
<td>$0.0 A</td>
</tr>
<tr>
<td>2018</td>
<td>$0.0 E</td>
<td>$0.0 E</td>
<td>$0.0 E</td>
<td>$0.0 E</td>
<td>$0.0 E</td>
</tr>
<tr>
<td>2019</td>
<td>$0.0 E</td>
<td>$0.0 E</td>
<td>$0.0 E</td>
<td>$0.0 E</td>
<td>$0.0 E</td>
</tr>
<tr>
<td>2020</td>
<td>$0.0 E</td>
<td>$0.0 E</td>
<td>$0.0 E</td>
<td>$0.0 E</td>
<td>$0.0 E</td>
</tr>
</tbody>
</table>

**ZACKS ESTIMATES**

- **Shares Outstanding (mil)**: 247  
- **Market Capitalization ($mil)**: $64.2  
- **Short Interest Ratio (days)**: 1.02  
- **Institutional Ownership (%)**: N/A  
- **Insider Ownership (%)**: N/A  
- **Annual Cash Dividend**: $0.00  
- **Dividend Yield (%)**: 0.00

**5-Yr. Historical Growth Rates**

<table>
<thead>
<tr>
<th>2017</th>
<th>Q1 (Mar)</th>
<th>Q2 (Jun)</th>
<th>Q3 (Sep)</th>
<th>Q4 (Dec)</th>
<th>Year (Dec)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>-$0.01 A</td>
<td>-$0.01 A</td>
<td>-$0.01 A</td>
<td>-$0.01 A</td>
<td>-$0.03 A</td>
</tr>
<tr>
<td>N/A</td>
<td>-$0.01 A</td>
<td>-$0.01 A</td>
<td>-$0.01 A</td>
<td>-$0.01 E</td>
<td>-$0.04 E</td>
</tr>
</tbody>
</table>

**P/E using TTM EPS**: N/A
**P/E using 2018 Estimate**: N/A
**P/E using 2019 Estimate**: N/A

**Zacks Rank**: N/A
WHAT'S NEW

Third Quarter 2018 Results

ProMIS Neurosciences Inc. (TSE: PMN) has experienced a busy quarter since our previous report providing presentations and press releases addressing the:

- safety profile of PMN310 with respect to BAN2401 and aducanumab;
- the importance of selectivity against toxic oligomers; and
- the advancement of monoclonal antibody candidates targeting epitopes appearing on toxic oligomers for α-synuclein.

Financial results for the period were provided in a press release and SEDAR filings released on November 13, 2018 and company CEO Elliot Goldstein narrated an overview of the year on November 20.

The company continued to advance its programs in the third quarter and expended $2.9 million in this endeavor. Research and development expenses were $1.9 million, up 42% compared to the prior year due to higher research program costs for the Alzheimer’s Disease program, greater recruiting expenses and higher costs to support its patent portfolio, partially offset by lower stock-based compensation. General and administrative expenses were $1.0 million in the period, rising 240% on higher consultant salaries and related costs, other professional fees, investor and public relations and stock-based compensation. No service or product revenues were generated for this preclinical company.

Cash stood at $4.7 million, declining $2.1 million sequentially. Cash burn in the quarter was ($2.4) million partially offset by $0.2 million of cash generated from warrant exercises. Current cash levels are expected to provide sufficient funding to support operations until 2Q:19.

ProMIS anticipates continued advancement of the Alzheimer’s Disease (AD) portfolio and PMN310 in preclinical development. Phase I clinical trial results for PMN310 are expected to be ready by 2020. Other programs are also targeted for advancement including Tau in AD, TDP43 and SOD1 in amyotrophic lateral sclerosis (ALS) and α-synuclein for Parkinson’s Disease (PD) as illustrated below in the company’s pipeline.

Exhibit I – ProMIS Neurosciences Product Portfolio

<table>
<thead>
<tr>
<th>Target identification</th>
<th>Antibody generation</th>
<th>Preclinical validation</th>
<th>IND enabling</th>
<th>Phase 1*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PMN310 – IND Enabling</strong></td>
<td>Novel targets identified</td>
<td>Lead Antibody Selection</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Amyloidβ Alzheimer’s</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TDP43: ALS &amp; Frontotemporal Dementia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SOD1: ALS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>α-synuclein Parkinson’s &amp; Gray Body Dementia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 Currency is denominated in Canadian Dollars
Proposed Phase I Trial Design

ProMIS has provided some detail regarding its anticipated Phase I trial for PMN310; however, trial design remains in progress. There will be a strong emphasis on selecting useful biomarkers and several are being explored, especially ones that require a blood draw as opposed to cerebral spinal fluid. One biomarker in particular that has shown promise is Neurofilament Light Chain (NFL), which may be useful for measuring neuronal death. Neurofilaments are byproducts of neuroaxonal breakdown and can indicate neurodegeneration. We anticipate results from the trial will be available in 2020. In addition to measuring safety, the study will use validated biomarkers to measure dose dependent treatment effect. Low doses from 0.3 mg/kg to 1.0 mg/kg will be administered to healthy normal volunteers to identify any safety signals. As the trial progresses to higher doses, Alzheimer's patients will be treated at various dose levels ranging from 3, 10, 20 and 40 mg/kg. We anticipate further detail as the trial approaches.

Exhibit II – PMN310 Phase I Trial Design

α-synuclein Target

In October, ProMIS announced a milestone related to the advance of its Parkinson's Disease (PD) efforts. The company was able to identify monoclonal antibodies that will specifically bind to α-synuclein toxic oligomers and detailed the discovery in a press release. We provided some background on ProMIS PD program and PD itself in an article highlighting α-synuclein, the stages of PD and the current paradigm that is applicable to the disease.

AAIC Presentation

In July, ProMIS participated in the Alzheimer's Association International Conference (AAIC) and presented a poster highlighting PMN310's ability to bind to toxic oligomers. The poster provided several conclusions:

- humanized PMN310 provides better potency and safety as compared to other amyloid beta directed antibodies;
- PMN310's key characteristics allow for greater safety at higher doses; and,
- greater selectivity can allow for a higher effective dose.

The following exhibit is taken from the poster and illustrates the binding response of humanized PMN310. ProMIS' monoclonal antibody is compared to Biogen's Phase III candidate aducanumab and Pfizer's former Phase III and abandoned bapineuzumab.

---

2 The poster by Kaplan (et al.), is entitled Humanized PMN310 shows enhanced therapeutic potential by binding toxic low molecular weight Aβ oligomers while avoiding ARIA-related binding to Aβ deposits in AD patient brains.
3 Key characteristics of PMN310 include no binding to amyloid beta plaques and the use of the IgG4 isotype, which limit the incidence of amyloid-related imaging abnormalities (ARIA) edema or brain swelling.
In conjunction with the AAIC conference, ProMIS’ Chief Development Officer, Dr. Johanne Kaplan submitted a white paper and video presentation which we discuss here. Following the conference, ProMIS provided commentary on the key themes at the meeting.

**Plaque Binding**

On August 21 the company announced results demonstrating the lack of binding affinity between PMN310 and amyloid beta plaques. This result was compared to the binding of BAN2401 and aducanumab where robust amyloid beta plaque reactivity was observed. This result is important because it means that PMN310 is less likely to be diluted by plaque binding and greater amounts of the monoclonal antibody can target and bind to toxic oligomers. This targeted binding can also provide an improved safety profile by avoiding ARIA-E. Below are images of brain section exposed to PMN310 and other leading candidates for AD. Brown sections show the binding of antibodies to plaques in the brain. Absence of this stain indicates the desired lack of binding to inert plaques.
**Significant Event Timeline**

ProMIS has a number of recent and upcoming milestones related to development of its pipeline which we chronologically summarize below.

- PMN 310 named lead development candidate – 1Q:17
- White paper on AD failures and toxic oligomers – 1Q:17
- Private placement for CAD$2.7 MM – 1Q:17
- Anthony Giovannazzo added to board – 1Q:17
- Daniel Geffken appointed as CFO – 1Q:17
- ALS TDP43 patent filed – 2Q:17
- OTCQB Listing (ARFXF) – 4Q:17
- GLP Toxicology – 2018
- Initiate PMN310 Manufacturing – 2Q:18
- Private Placement for CAD$7.2 MM – 2Q:18
- Participation in AAIC – 2Q:18
- Appointment of James Kupiec, MD as CMO – 3Q:18
- Identification of α-synuclein targeting candidates for PD – 4Q:18
- Prepare for IND and Phase I trial for PMN310 - 2019
- Generate Phase I biomarker data - 2020

**Summary**

ProMIS has continued to move forward with its preclinical PMN310 work and is expected to advance its IND-enabling work and identify relevant biomarkers for its clinical trials. Parallel with these efforts is continued interaction with the scientific, investment and corporate community to present the promise of PMN310 and other pipeline candidates to garner KOL support, financing and partnerships. We believe ProMIS represents an attractive opportunity to gain exposure to an immense disease area with no other approved therapies. There are almost six million persons with AD in the US and over 30 million outside of the US that suffer from the disease. Additionally, there is a larger population with MCI and pre-Alzheimer’s which may benefit even more from toxic oligomer sequestering therapy. The path forward is relatively clear with other assets including aducanumab setting the precedent for trial design. We update our model to reflect third quarter 2018 actuals and maintain our valuation of CAD$7.00.
## PROJECTED FINANCIALS

**ProMIS Neurosciences Inc - Income Statement**

<table>
<thead>
<tr>
<th>ProMIS Neurosciences Inc.</th>
<th>2017 A</th>
<th>Q1 A</th>
<th>Q2 A</th>
<th>Q3 A</th>
<th>Q4 E</th>
<th>2018 E</th>
<th>2019 E</th>
<th>2020 E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Revenues (CAD$)</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>$4.0</td>
<td>$0.8</td>
<td>$1.5</td>
<td>$1.9</td>
<td>$3.2</td>
<td>$7.4</td>
<td>$14.4</td>
<td>$16.9</td>
</tr>
<tr>
<td>G&amp;A</td>
<td>$2.1</td>
<td>$0.8</td>
<td>$0.7</td>
<td>$1.0</td>
<td>$0.5</td>
<td>$3.0</td>
<td>$2.7</td>
<td>$3.1</td>
</tr>
<tr>
<td>Operating Income</td>
<td>($6.0)</td>
<td>($1.6)</td>
<td>($2.2)</td>
<td>($2.9)</td>
<td>($3.7)</td>
<td>($10.4)</td>
<td>($17.1)</td>
<td>($20.0)</td>
</tr>
<tr>
<td>Amort of Financing &amp; Interest</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Pre-Tax Income</td>
<td>($6.0)</td>
<td>$1.6</td>
<td>($2.2)</td>
<td>($2.9)</td>
<td>($3.7)</td>
<td>($10.4)</td>
<td>($17.1)</td>
<td>($20.0)</td>
</tr>
<tr>
<td>Taxes &amp; Other</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Net Income</td>
<td>($6.0)</td>
<td>($1.6)</td>
<td>($2.2)</td>
<td>($2.9)</td>
<td>($3.7)</td>
<td>($10.4)</td>
<td>($17.1)</td>
<td>($20.0)</td>
</tr>
<tr>
<td>Reported EPS</td>
<td>($0.03)</td>
<td>($0.01)</td>
<td>($0.01)</td>
<td>($0.01)</td>
<td>($0.01)</td>
<td>($0.04)</td>
<td>($0.06)</td>
<td>($0.06)</td>
</tr>
<tr>
<td>YOY Growth</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shares Outstanding</td>
<td>205.8</td>
<td>223.9</td>
<td>239.4</td>
<td>246.4</td>
<td>255.0</td>
<td>241.2</td>
<td>295.0</td>
<td>345.0</td>
</tr>
</tbody>
</table>

*Source: Company Filing // Zacks Investment Research, Inc. Estimates*
HISTORICAL STOCK PRICE

ProMIS Neurosciences Inc – Historical Price Chart

Chart provided courtesy of www.barchart.com
DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research (“Zacks SCR”), a division of Zacks Investment Research (“ZIR”), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, John Vandermosten, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.

Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer’s business.

SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN DISCLAIMER

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada and is not an associated person of any Canadian registered adviser and/or dealer and, therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.